 Soligenix Inc NASDAQ: SNGX says that following the validation of synthetic hypericins biologic activity, the Company will be expanding the therapy under the research name SGX302 into psoriasis. Related Content: Soligenix Stock Moves Higher On US Orphan Drug Tag For T-cell Lymphoma Candidate. 